Investors like Novo growth, but can it continue?
This article was originally published in Scrip
Executive Summary
Since 4 August 2014, traders on the stock market have indicated that GlaxoSmithKline is worth less than Novo Nordisk ($112.5bn versus $116.5bn at the end of trading on 12 August, respectively). This has nothing to with current size and performance (Figure 1): GSK is a much bigger company, with revenue 2.8 times that of Novo and net profit (earnings) more than 2.3 times as big.
You may also be interested in...
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Stock Scan April 2018: Pharma's Fizz Falls Flat
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.